
DISTRICT OF COLUMBIA: Regulators at the US Food and Drug Administration on Monday granted market approval to Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD) for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The proprietary extract formulation – developed by the British biotechnology firm GW Pharmaceuticals – had Read the full article…